<?xml version="1.0" encoding="UTF-8"?>
<xocs:doc content-type="Abstract" dbname="scopusbase" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd xocs-ani515.xsd" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><xocs:meta>
    <xocs:eid>2-s2.0-85107985872</xocs:eid>
    <xocs:oeid/>
    <xocs:doi>10.1016/j.semarthrit.2021.05.007</xocs:doi>
    <xocs:pmid>34140182</xocs:pmid>
    <xocs:online-status>available</xocs:online-status>
    <xocs:pui>2013080071</xocs:pui>
    <xocs:pii>S0049017221000986</xocs:pii>
    <xocs:fulltext-eid score="81">1-s2.0-S0049017221000986</xocs:fulltext-eid>
    <xocs:sdfullavail>1</xocs:sdfullavail>
    <xocs:issn>00490172</xocs:issn>
    <xocs:volume>51</xocs:volume>
    <xocs:issue>4</xocs:issue>
    <xocs:author-surname>Maugesten</xocs:author-surname>
    <xocs:author-fi>Ø</xocs:author-fi>
    <xocs:firstpage>929</xocs:firstpage>
    <xocs:lastpage>932</xocs:lastpage>
    <xocs:sort-year>2021</xocs:sort-year>
    <xocs:sort-yyyymm>202108</xocs:sort-yyyymm>
    <xocs:pub-year>2021</xocs:pub-year>
    <xocs:timestamp yyyymmdd="20210924">2021-09-24T22:08:02.903397Z</xocs:timestamp>
    <xocs:orig-load-date yyyymmdd="20210622">2021-06-22</xocs:orig-load-date>
    <xocs:datesort>20210801</xocs:datesort>
    <xocs:indexeddate epoch="1624338506">2021-06-22T05:08:26.062612Z</xocs:indexeddate>
    <xocs:absavail>1</xocs:absavail>
    <xocs:suppressdummy>no</xocs:suppressdummy>
    <xocs:srctype>j</xocs:srctype>
    <xocs:subjareas><xocs:subjarea>MEDI</xocs:subjarea></xocs:subjareas>
    <xocs:srctitle>Seminars in Arthritis and Rheumatism</xocs:srctitle>
    <xocs:countries><xocs:country>Norway</xocs:country><xocs:country>Denmark</xocs:country><xocs:country>Belgium</xocs:country><xocs:country>Netherlands</xocs:country><xocs:country>France</xocs:country><xocs:country>United States</xocs:country><xocs:country>United Kingdom</xocs:country></xocs:countries>
    <xocs:languages><xocs:language>English</xocs:language></xocs:languages>
    <xocs:prefnameauids><xocs:prefnameauid>Maugesten#57216726004</xocs:prefnameauid><xocs:prefnameauid>Haugen, I.K.#23027744500</xocs:prefnameauid><xocs:prefnameauid>Pedersen, S.J.#36846188200</xocs:prefnameauid><xocs:prefnameauid>Mathew, A.J.#25930994300</xocs:prefnameauid><xocs:prefnameauid>Østergaard, M.#7005401205</xocs:prefnameauid><xocs:prefnameauid>Stoenoiu, M.S.#6602649826</xocs:prefnameauid><xocs:prefnameauid>Kroon, F.P.B.#55204718100</xocs:prefnameauid><xocs:prefnameauid>Kloppenburg, M.#6701738535</xocs:prefnameauid><xocs:prefnameauid>Gandjbakhch, F.#23567463900</xocs:prefnameauid><xocs:prefnameauid>Genant, H.K.#57205716435</xocs:prefnameauid><xocs:prefnameauid>Conaghan, P.G.#56371487500</xocs:prefnameauid><xocs:prefnameauid>Peterfy, C.#7006393065</xocs:prefnameauid></xocs:prefnameauids>
    <xocs:open-access><xocs:oa-article-status is-open-access="0">None</xocs:oa-article-status><xocs:upw-open-access><xocs:upw-oa-article-status>false</xocs:upw-oa-article-status><xocs:upw-timestamp>2021-09-01T17:04:59.000251Z</xocs:upw-timestamp><xocs:upw-oa-journal-is-oa>false</xocs:upw-oa-journal-is-oa><xocs:upw-oa-journal-is-in-doaj>false</xocs:upw-oa-journal-is-in-doaj></xocs:upw-open-access></xocs:open-access>
    <xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2021-08-25T23:24:32.069Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined</xocs:funding-addon-type><xocs:funding><xocs:funding-agency-matched-string>ExtraFoundation for Health and Rehabilitation</xocs:funding-agency-matched-string></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>IMI-APPROACH</xocs:funding-agency-matched-string></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Pahles Foundation/the Norwegian Rheumatism Association</xocs:funding-agency-matched-string></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Wife?s Research Foundation</xocs:funding-agency-matched-string></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Pfizer</xocs:funding-agency-matched-string><xocs:funding-agency>Pfizer</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100004319</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/6252001/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Merck</xocs:funding-agency-matched-string><xocs:funding-agency>Merck</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100004334</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/6252001/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Roche</xocs:funding-agency-matched-string><xocs:funding-agency>Roche</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100004337</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/2658434/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Abbvie</xocs:funding-agency-matched-string><xocs:funding-agency>AbbVie</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100006483</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/6252001/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>UCB</xocs:funding-agency-matched-string><xocs:funding-agency>UCB</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/100011110</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/2802361/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>National Institute for Health Research</xocs:funding-agency-matched-string><xocs:funding-agency-acronym>NIHR</xocs:funding-agency-acronym><xocs:funding-agency>National Institute for Health Research</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100000272</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/2635167/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>South-Eastern Norway Regional Health Authority</xocs:funding-agency-matched-string><xocs:funding-agency-acronym>sorost</xocs:funding-agency-acronym><xocs:funding-agency>Helse Sør-Øst RHF</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100006095</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/3144096/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Trygve Gythfeldt and Wife´s Research Foundation</xocs:funding-agency-matched-string><xocs:funding-agency>Dr Trygve Gythfeldt og Frues Forskningsfond</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100008570</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/3144096/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Simon Fougner Hartmanns Family Foundation</xocs:funding-agency-matched-string><xocs:funding-agency>Simon Fougner Hartmanns Familiefond</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100011076</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/2623032/</xocs:funding-agency-country></xocs:funding><xocs:funding><xocs:funding-agency-matched-string>Leeds Biomedical Research center</xocs:funding-agency-matched-string><xocs:funding-agency-acronym>Leeds BRC</xocs:funding-agency-acronym><xocs:funding-agency>Leeds Biomedical Research Centre</xocs:funding-agency><xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100018955</xocs:funding-agency-id><xocs:funding-agency-country>http://sws.geonames.org/2635167/</xocs:funding-agency-country></xocs:funding><xocs:funding-text>We would like to thank all participants in the OMERACT MRI special interest group (SIG) for input in the project. Thanks to Sjoerd van Beest for participating in the first reliability exercise. We would also like to thank all participants in the Nor-Hand study. PGC is supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research center, United Kingdom. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. </xocs:funding-text><xocs:funding-text>Dr. Peterfy reports contract research from AbbVie, Centrexion, Flexion Therapeutics, Paradigm Biopharmaceuticals, Regeneron. Dr. Kloppenburg reports consultancy (Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR) and local investigator of industry-driven trial (Abbvie), from Wolters Kluwer (UptoDate), Springer Verlag (Reumatologie en klinische immunologie), grants from Pfizer, grants from IMI-APPROACH. Dr. ?stergaard reports grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Merck, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from UCB, grants and personal fees from Celgene, personal fees from Sanofi, personal fees from Regeneron, grants, personal fees and non-financial support from Novartis, personal fees from Gilead. Dr. Haugen has received grants from Pfizer (Advance) and has been in advisory board for Abbvie; All outside the submitted work. There are no relevant disclosures for the remaining authors. The Nor-Hand study was supported by funds from the South-Eastern Norway Regional Health Authority, the Pahles Foundation/the Norwegian Rheumatism Association, the Simon Fougner Hartmanns Family Foundation, and the Trygve Gythfeldt and Wife?s Research Foundation. The ExtraFoundation for Health and Rehabilitation through EXTRA funds has financed the PhD position of ?ystein Maugesten.</xocs:funding-text><xocs:funding-text>Dr. Peterfy reports contract research from AbbVie, Centrexion, Flexion Therapeutics, Paradigm Biopharmaceuticals, Regeneron. Dr. Kloppenburg reports consultancy (Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR) and local investigator of industry-driven trial (Abbvie), from Wolters Kluwer (UptoDate), Springer Verlag (Reumatologie en klinische immunologie), grants from Pfizer, grants from IMI-APPROACH. Dr. Østergaard reports grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Merck, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from UCB, grants and personal fees from Celgene, personal fees from Sanofi, personal fees from Regeneron, grants, personal fees and non-financial support from Novartis, personal fees from Gilead. Dr. Haugen has received grants from Pfizer (Advance) and has been in advisory board for Abbvie; All outside the submitted work. There are no relevant disclosures for the remaining authors. The Nor-Hand study was supported by funds from the South-Eastern Norway Regional Health Authority, the Pahles Foundation/the Norwegian Rheumatism Association, the Simon Fougner Hartmanns Family Foundation, and the Trygve Gythfeldt and Wife´s Research Foundation. The ExtraFoundation for Health and Rehabilitation through EXTRA funds has financed the PhD position of Øystein Maugesten. </xocs:funding-text></xocs:funding-list>
    <cto:doctype>ar</cto:doctype>
    <cto:group-id>85107985872</cto:group-id>
    <cto:ref-id>84860919649</cto:ref-id>
    <cto:ref-id>84954326530</cto:ref-id>
    <cto:ref-id>84946562060</cto:ref-id>
    <cto:ref-id>85054550608</cto:ref-id>
    <cto:ref-id>85045580718</cto:ref-id>
    <cto:ref-id>85075519551</cto:ref-id>
    <cto:ref-id>84960193713</cto:ref-id>
    <cto:ref-id>84992161278</cto:ref-id>
    <cto:ref-id>85054819392</cto:ref-id>
    <cto:ref-id>85062991715</cto:ref-id>
    <cto:ref-id>85108007533</cto:ref-id>
    <cto:ref-id>84893568799</cto:ref-id>
    <cto:ref-id>85029949343</cto:ref-id>
    <cto:ref-id>85070203338</cto:ref-id>
    <cto:ref-id>85029912697</cto:ref-id>
    <cto:ref-id>85107962632</cto:ref-id>
    <cto:unique-author seq="1"><cto:auth-initials>Ø.</cto:auth-initials><cto:auth-indexed-name>Maugesten O.</cto:auth-indexed-name><cto:auth-surname>Maugesten</cto:auth-surname><cto:auth-id>57216726004</cto:auth-id><cto:auth-e-address type="email">oystein.maugesten@gmail.com</cto:auth-e-address></cto:unique-author>
    <cto:unique-author seq="2"><cto:auth-initials>S.J.</cto:auth-initials><cto:auth-indexed-name>Pedersen S.J.</cto:auth-indexed-name><cto:auth-surname>Pedersen</cto:auth-surname><cto:auth-id>36846188200</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="3"><cto:auth-initials>M.S.</cto:auth-initials><cto:auth-indexed-name>Stoenoiu M.S.</cto:auth-indexed-name><cto:auth-surname>Stoenoiu</cto:auth-surname><cto:auth-id>6602649826</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="4"><cto:auth-initials>F.P.B.</cto:auth-initials><cto:auth-indexed-name>Kroon F.P.B.</cto:auth-indexed-name><cto:auth-surname>Kroon</cto:auth-surname><cto:auth-id>55204718100</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="5"><cto:auth-initials>A.J.</cto:auth-initials><cto:auth-indexed-name>Mathew A.J.</cto:auth-indexed-name><cto:auth-surname>Mathew</cto:auth-surname><cto:auth-id>25930994300</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="6"><cto:auth-initials>H.K.</cto:auth-initials><cto:auth-indexed-name>Genant H.K.</cto:auth-indexed-name><cto:auth-surname>Genant</cto:auth-surname><cto:auth-id>57205716435</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="7"><cto:auth-initials>P.G.</cto:auth-initials><cto:auth-indexed-name>Conaghan P.G.</cto:auth-indexed-name><cto:auth-surname>Conaghan</cto:auth-surname><cto:auth-id>56371487500</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="8"><cto:auth-initials>F.</cto:auth-initials><cto:auth-indexed-name>Gandjbakhch F.</cto:auth-indexed-name><cto:auth-surname>Gandjbakhch</cto:auth-surname><cto:auth-id>23567463900</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="9"><cto:auth-initials>M.</cto:auth-initials><cto:auth-indexed-name>Kloppenburg M.</cto:auth-indexed-name><cto:auth-surname>Kloppenburg</cto:auth-surname><cto:auth-id>6701738535</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="10"><cto:auth-initials>C.</cto:auth-initials><cto:auth-indexed-name>Peterfy C.</cto:auth-indexed-name><cto:auth-surname>Peterfy</cto:auth-surname><cto:auth-id>7006393065</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="11"><cto:auth-initials>M.</cto:auth-initials><cto:auth-indexed-name>Ostergaard M.</cto:auth-indexed-name><cto:auth-surname>Østergaard</cto:auth-surname><cto:auth-id>7005401205</cto:auth-id></cto:unique-author>
    <cto:unique-author seq="12"><cto:auth-initials>I.K.</cto:auth-initials><cto:auth-indexed-name>Haugen I.K.</cto:auth-indexed-name><cto:auth-surname>Haugen</cto:auth-surname><cto:auth-id>23027744500</cto:auth-id></cto:unique-author>
    <cto:unique-auth-count>12</cto:unique-auth-count>
  </xocs:meta><xocs:item><item><ait:process-info><ait:date-delivered year="2021" month="09" day="24" timestamp="2021-09-24T13:49:50.000050-04:00"/><ait:date-sort year="2021" month="08" day="01"/><ait:status type="core" state="update" stage="S300"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2021 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:pii>S0049017221000986</ce:pii><ce:doi>10.1016/j.semarthrit.2021.05.007</ce:doi><ce:ern>pii:S0049017221000986</ce:ern><itemid idtype="PUI">2013080071</itemid><itemid idtype="CAR-ID">933814319</itemid><itemid idtype="EMBASE">20210587216</itemid><itemid idtype="MEDL">34140182</itemid><itemid idtype="NURSNG">2021272442</itemid><itemid idtype="REAXYSCAR">20212432627</itemid><itemid idtype="SCOPUS">20212017637</itemid><itemid idtype="SCP">85107985872</itemid><itemid idtype="SGR">85107985872</itemid><itemid idtype="PUIsecondary">635370970</itemid><itemid idtype="OSIN">76625699</itemid></itemidlist><history><date-created year="2021" month="08" day="25" timestamp="BST 08:03:54"/></history><dbcollection>EMBASE</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>NURSNG</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>SCOPUS</dbcollection><dbcollection>Scopusbase</dbcollection><external-source>Publisher</external-source></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng" original="y">Hand</author-keyword><author-keyword xml:lang="eng" original="y">MRI</author-keyword><author-keyword xml:lang="eng" original="y">OMERACT</author-keyword><author-keyword xml:lang="eng" original="y">Osteoarthritis</author-keyword><author-keyword xml:lang="eng" original="y">Synovitis</author-keyword></author-keywords></citation-info><citation-title><titletext xml:lang="eng" original="y" language="English">Reliability and agreement of proton density-weighted vs. gadolinium-enhanced T1-weighted MRI in hand osteoarthritis. An OMERACT MRI special interest group reliability exercise</titletext></citation-title><author-group><author auid="57216726004" seq="1" type="auth" author-instance-id="S0049017221000986-4094ae9068a19652deb0b81d222583f8"><ce:initials>Ø.</ce:initials><ce:indexed-name>Maugesten O.</ce:indexed-name><ce:surname>Maugesten</ce:surname><preferred-name><ce:initials/><ce:indexed-name>Maugesten </ce:indexed-name><ce:surname>Maugesten</ce:surname><ce:given-name/></preferred-name><ce:e-address type="email">oystein.maugesten@gmail.com</ce:e-address></author><author auid="23027744500" seq="12" type="auth" author-instance-id="S0049017221000986-ea2198d42828eeb2548fa23040d5de4b"><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname><preferred-name><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname><ce:given-name>I. K.</ce:given-name></preferred-name></author><affiliation afid="60069317" dptid="124469379" country="nor" affiliation-instance-id="S0049017221000986-ad53acb3ba53ef330f8a2cb1c2b58ff3"><organization>Division of Rheumatology and Research</organization><organization>Diakonhjemmet Hospital</organization><address-part>Box 23 Vinderen</address-part><city>Oslo</city><postal-code>N-0319</postal-code><ce:source-text>aDivision of Rheumatology and Research, Diakonhjemmet Hospital, Box 23 Vinderen, Oslo N-0319, Norway</ce:source-text><affiliation-id afid="60069317" dptid="124469379"/><country>Norway</country></affiliation></author-group><author-group><author auid="57216726004" seq="1" type="auth" author-instance-id="S0049017221000986-4094ae9068a19652deb0b81d222583f8"><ce:initials>Ø.</ce:initials><ce:indexed-name>Maugesten O.</ce:indexed-name><ce:surname>Maugesten</ce:surname><preferred-name><ce:initials/><ce:indexed-name>Maugesten </ce:indexed-name><ce:surname>Maugesten</ce:surname><ce:given-name/></preferred-name><ce:e-address type="email">oystein.maugesten@gmail.com</ce:e-address></author><affiliation afid="60003938" country="nor" affiliation-instance-id="S0049017221000986-fa855a9f5e426fdbf0fa160bcef65f65"><organization>Faculty of Medicine</organization><organization>University of Oslo</organization><city>Oslo</city><ce:source-text>bFaculty of Medicine, University of Oslo, Oslo, Norway</ce:source-text><affiliation-id afid="60003938"/><affiliation-id afid="60010348"/><country>Norway</country></affiliation></author-group><author-group><author auid="36846188200" seq="2" type="auth" author-instance-id="S0049017221000986-5050bf9797bb88fd9f9fe58e743ea986"><ce:initials>S.J.</ce:initials><ce:indexed-name>Pedersen S.J.</ce:indexed-name><ce:surname>Pedersen</ce:surname><preferred-name><ce:initials>S.J.</ce:initials><ce:indexed-name>Pedersen S.J.</ce:indexed-name><ce:surname>Pedersen</ce:surname><ce:given-name>S. J.</ce:given-name></preferred-name></author><author auid="25930994300" seq="5" type="auth" author-instance-id="S0049017221000986-8a0df4eb0411253790a3b170c9bf03e3"><ce:initials>A.J.</ce:initials><ce:indexed-name>Mathew A.J.</ce:indexed-name><ce:surname>Mathew</ce:surname><preferred-name><ce:initials>A.J.</ce:initials><ce:indexed-name>Mathew A.J.</ce:indexed-name><ce:surname>Mathew</ce:surname><ce:given-name>A. J.</ce:given-name></preferred-name></author><author auid="7005401205" seq="11" type="auth" author-instance-id="S0049017221000986-4b6c73843173c4de82cb88632c316407"><ce:initials>M.</ce:initials><ce:indexed-name>Ostergaard M.</ce:indexed-name><ce:surname>Østergaard</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Østergaard M.</ce:indexed-name><ce:surname>Østergaard</ce:surname><ce:given-name>M.</ce:given-name></preferred-name></author><affiliation afid="60006564" dptid="115766115" country="dnk" affiliation-instance-id="S0049017221000986-b9da614dbf746bcaefb75238969e68ed"><organization>Copenhagen Center for Arthritis Research</organization><organization>Center for Rheumatology and Spine Diseases</organization><organization>Rigshospitalet</organization><city>Copenhagen</city><ce:source-text>cCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark</ce:source-text><affiliation-id afid="60006564" dptid="115766115"/><country>Denmark</country></affiliation></author-group><author-group><author auid="6602649826" seq="3" type="auth" author-instance-id="S0049017221000986-60006b88c05ee260cbdf7a21b48a6fd2"><ce:initials>M.S.</ce:initials><ce:indexed-name>Stoenoiu M.S.</ce:indexed-name><ce:surname>Stoenoiu</ce:surname><preferred-name><ce:initials>M.S.</ce:initials><ce:indexed-name>Stoenoiu M.S.</ce:indexed-name><ce:surname>Stoenoiu</ce:surname><ce:given-name>M. S.</ce:given-name></preferred-name></author><affiliation afid="60012936" dptid="103682083" country="bel" affiliation-instance-id="S0049017221000986-497c080e3f315dd589b809f2259f197a"><organization>Department of Rheumatology</organization><organization>Cliniques Universitaires Saint Luc</organization><city>Brussels</city><ce:source-text>dDepartment of Rheumatology, Cliniques Universitaires Saint Luc, Brussels, Belgium</ce:source-text><affiliation-id afid="60012936" dptid="103682083"/><country>Belgium</country></affiliation></author-group><author-group><author auid="6602649826" seq="3" type="auth" author-instance-id="S0049017221000986-60006b88c05ee260cbdf7a21b48a6fd2"><ce:initials>M.S.</ce:initials><ce:indexed-name>Stoenoiu M.S.</ce:indexed-name><ce:surname>Stoenoiu</ce:surname><preferred-name><ce:initials>M.S.</ce:initials><ce:indexed-name>Stoenoiu M.S.</ce:indexed-name><ce:surname>Stoenoiu</ce:surname><ce:given-name>M. S.</ce:given-name></preferred-name></author><affiliation afid="60000874" dptid="109219906" country="bel" affiliation-instance-id="S0049017221000986-7d2bb1c09d771a7bae559a7b946cf38a"><organization>Institut de Recherche Expérimentale et Clinique</organization><organization>Université catholique de Louvain</organization><ce:source-text>eInstitut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Belgium</ce:source-text><affiliation-id afid="60000874" dptid="109219906"/><country>Belgium</country></affiliation></author-group><author-group><author auid="55204718100" seq="4" type="auth" author-instance-id="S0049017221000986-0a1a393f009af14e06e3094a6e72b51a"><ce:initials>F.P.B.</ce:initials><ce:indexed-name>Kroon F.P.B.</ce:indexed-name><ce:surname>Kroon</ce:surname><preferred-name><ce:initials>F.P.B.</ce:initials><ce:indexed-name>Kroon F.P.B.</ce:indexed-name><ce:surname>Kroon</ce:surname><ce:given-name>F. P.B.</ce:given-name></preferred-name></author><author auid="6701738535" seq="9" type="auth" author-instance-id="S0049017221000986-badd62c82d5f21178e7b7f41b720a854"><ce:initials>M.</ce:initials><ce:indexed-name>Kloppenburg M.</ce:indexed-name><ce:surname>Kloppenburg</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Kloppenburg M.</ce:indexed-name><ce:surname>Kloppenburg</ce:surname><ce:given-name>M.</ce:given-name></preferred-name></author><affiliation afid="60015618" dptid="113409467" country="nld" affiliation-instance-id="S0049017221000986-62846cccb51ed1e4d848f2a2fe5578c7"><organization>Department of Rheumatology</organization><organization>Leiden University Medical Center</organization><city>Leiden</city><ce:source-text>fDepartment of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands</ce:source-text><affiliation-id afid="60015618" dptid="113409467"/><country>Netherlands</country></affiliation></author-group><author-group><author auid="55204718100" seq="4" type="auth" author-instance-id="S0049017221000986-0a1a393f009af14e06e3094a6e72b51a"><ce:initials>F.P.B.</ce:initials><ce:indexed-name>Kroon F.P.B.</ce:indexed-name><ce:surname>Kroon</ce:surname><preferred-name><ce:initials>F.P.B.</ce:initials><ce:indexed-name>Kroon F.P.B.</ce:indexed-name><ce:surname>Kroon</ce:surname><ce:given-name>F. P.B.</ce:given-name></preferred-name></author><affiliation afid="125862326" dptid="126414761" country="nld" affiliation-instance-id="S0049017221000986-965a22b5818857169de0de47dfcdaed8"><organization>Department of Rheumatology</organization><organization>Zuyderland Medical Center</organization><city>Heerlen</city><ce:source-text>gDepartment of Rheumatology, Zuyderland Medical Center, Heerlen, the Netherlands</ce:source-text><affiliation-id afid="125862326" dptid="126414761"/><country>Netherlands</country></affiliation></author-group><author-group><author auid="25930994300" seq="5" type="auth" author-instance-id="S0049017221000986-8a0df4eb0411253790a3b170c9bf03e3"><ce:initials>A.J.</ce:initials><ce:indexed-name>Mathew A.J.</ce:indexed-name><ce:surname>Mathew</ce:surname><preferred-name><ce:initials>A.J.</ce:initials><ce:indexed-name>Mathew A.J.</ce:indexed-name><ce:surname>Mathew</ce:surname><ce:given-name>A. J.</ce:given-name></preferred-name></author><author auid="7005401205" seq="11" type="auth" author-instance-id="S0049017221000986-4b6c73843173c4de82cb88632c316407"><ce:initials>M.</ce:initials><ce:indexed-name>Ostergaard M.</ce:indexed-name><ce:surname>Østergaard</ce:surname><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Østergaard M.</ce:indexed-name><ce:surname>Østergaard</ce:surname><ce:given-name>M.</ce:given-name></preferred-name></author><affiliation afid="60013332" dptid="113834890" country="dnk" affiliation-instance-id="S0049017221000986-6473fc808de802601f49a2477e9a7c09"><organization>Department of Clinical Medicine</organization><organization>Faculty of Health and Medical Sciences University of Copenhagen</organization><city>Copenhagen</city><ce:source-text>hDepartment of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen, Copenhagen, Denmark</ce:source-text><affiliation-id afid="60013332" dptid="113834890"/><affiliation-id afid="60030840"/><country>Denmark</country></affiliation></author-group><author-group><author auid="23567463900" seq="8" type="auth" author-instance-id="S0049017221000986-dc4775182bde431006239a072305968a"><ce:initials>F.</ce:initials><ce:indexed-name>Gandjbakhch F.</ce:indexed-name><ce:surname>Gandjbakhch</ce:surname><preferred-name><ce:initials>F.</ce:initials><ce:indexed-name>Gandjbakhch F.</ce:indexed-name><ce:surname>Gandjbakhch</ce:surname><ce:given-name>F.</ce:given-name></preferred-name></author><affiliation afid="60001422" dptid="108421547" country="fra" affiliation-instance-id="S0049017221000986-72794c17357afcc0e08cb4b69ad67405"><organization>Department of Rheumatology</organization><organization>Sorbonne University</organization><organization>APHP</organization><organization>Pitié-Salpêtrière Hospital</organization><city>Paris</city><ce:source-text>iDepartment of Rheumatology, Sorbonne University, APHP, Pitié-Salpêtrière Hospital, Paris, France</ce:source-text><affiliation-id afid="60001422" dptid="108421547"/><affiliation-id afid="60015622"/><affiliation-id afid="60021567"/><country>France</country></affiliation></author-group><author-group><author auid="57205716435" seq="6" type="auth" author-instance-id="S0049017221000986-765f5576a9de65868dea737bcf95b9ba"><ce:initials>H.K.</ce:initials><ce:indexed-name>Genant H.K.</ce:indexed-name><ce:surname>Genant</ce:surname><preferred-name><ce:initials>H.K.</ce:initials><ce:indexed-name>Genant H.K.</ce:indexed-name><ce:surname>Genant</ce:surname><ce:given-name>H. K.</ce:given-name></preferred-name></author><affiliation afid="60023691" country="usa" affiliation-instance-id="S0049017221000986-25f552ecbe8bc822bbc39b567ba32b55"><organization>Department of radiology and biomedical imaging</organization><organization>University of California</organization><city>San Francisco</city><ce:source-text>jDepartment of radiology and biomedical imaging, University of California, San Francisco, United States</ce:source-text><affiliation-id afid="60023691"/><affiliation-id afid="60017994"/><country>United States</country></affiliation></author-group><author-group><author auid="56371487500" seq="7" type="auth" author-instance-id="S0049017221000986-5fec8f559f8619fb88e2d4de55557390"><ce:initials>P.G.</ce:initials><ce:indexed-name>Conaghan P.G.</ce:indexed-name><ce:surname>Conaghan</ce:surname><preferred-name><ce:initials>P.G.</ce:initials><ce:indexed-name>Conaghan P.G.</ce:indexed-name><ce:surname>Conaghan</ce:surname><ce:given-name>P. G.</ce:given-name></preferred-name></author><affiliation afid="60170333" country="gbr" affiliation-instance-id="S0049017221000986-444d830c6748723625414203fe8053de"><organization>Leeds Institute of Rheumatic and Musculoskeletal Medicine</organization><organization>University of Leeds and NIHR Leeds Biomedical Research Centre</organization><city>Leeds</city><ce:source-text>kLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK</ce:source-text><affiliation-id afid="60170333"/><affiliation-id afid="60023959"/><affiliation-id afid="60012070"/><country>United Kingdom</country></affiliation></author-group><author-group><author auid="7006393065" seq="10" type="auth" author-instance-id="S0049017221000986-381bb43c3fe571424cb0e74e769e3305"><ce:initials>C.</ce:initials><ce:indexed-name>Peterfy C.</ce:indexed-name><ce:surname>Peterfy</ce:surname><preferred-name><ce:initials>C.</ce:initials><ce:indexed-name>Peterfy C.</ce:indexed-name><ce:surname>Peterfy</ce:surname><ce:given-name>C.</ce:given-name></preferred-name></author><affiliation country="usa" affiliation-instance-id="S0049017221000986-33fc678eae3abbffb4edcd3c7c1cfa6e"><organization>Spire Sciences</organization><organization>Inc.</organization><city>Boca Raton</city><state>FL</state><postal-code>33487</postal-code><ce:source-text>lSpire Sciences, Inc., Boca Raton, FL 33487, United States</ce:source-text><country>United States</country></affiliation></author-group><correspondence><person><ce:initials>Ø.</ce:initials><ce:indexed-name>Maugesten O.</ce:indexed-name><ce:surname>Maugesten</ce:surname></person><affiliation country="nor"><organization>Division of Rheumatology and Research</organization><organization>Diakonhjemmet Hospital</organization><address-part>Box 23 Vinderen</address-part><city>Oslo</city><postal-code>N-0319</postal-code><country>Norway</country></affiliation><ce:e-address type="email">oystein.maugesten@gmail.com</ce:e-address></correspondence><grantlist complete="y"><grant-text xml:lang="eng">Dr. Peterfy reports contract research from AbbVie, Centrexion, Flexion Therapeutics, Paradigm Biopharmaceuticals, Regeneron. Dr. Kloppenburg reports consultancy (Abbvie, Pfizer, Levicept, GlaxoSmithKline, Merck-Serono, Kiniksa, Flexion, Galapagos, Jansen, CHDR) and local investigator of industry-driven trial (Abbvie), from Wolters Kluwer (UptoDate), Springer Verlag (Reumatologie en klinische immunologie), grants from Pfizer, grants from IMI-APPROACH. Dr. Østergaard reports grants, personal fees and non-financial support from AbbVie, grants, personal fees and non-financial support from BMS, personal fees from Boehringer-Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Janssen, grants, personal fees and non-financial support from Merck, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from UCB, grants and personal fees from Celgene, personal fees from Sanofi, personal fees from Regeneron, grants, personal fees and non-financial support from Novartis, personal fees from Gilead. Dr. Haugen has received grants from Pfizer (Advance) and has been in advisory board for Abbvie; All outside the submitted work. There are no relevant disclosures for the remaining authors. The Nor-Hand study was supported by funds from the South-Eastern Norway Regional Health Authority, the Pahles Foundation/the Norwegian Rheumatism Association, the Simon Fougner Hartmanns Family Foundation, and the Trygve Gythfeldt and Wife´s Research Foundation. The ExtraFoundation for Health and Rehabilitation through EXTRA funds has financed the PhD position of Øystein Maugesten.</grant-text></grantlist><abstracts><abstract original="y" xml:lang="eng"><publishercopyright>© 2021 Elsevier Inc.</publishercopyright><ce:para>Objectives: To compare reliabilities of assessing synovitis in hand osteoarthritis (OA) using Magnetic Resonance Imaging (MRI) with/without gadolinium (Gd). Methods: Three readers scored synovitis on non-enhanced two-dimensional (2D) proton density (PD)-weighted MRI and Gd-enhanced (3D) MRI of hand joints in 20 patients. Inter-reader reliabilities were examined. Results: Reliability was good for Gd-enhanced MRI, but poor for non-enhanced PD-weighted MRI (intraclass correlation coefficient 0.83 and 0.21, respectively). Agreement between the two sequences was poor (weighted kappa 0.18). Conclusion: Gd-enhanced MRI was more reliable than PD-weighted MRI for assessing synovitis. Gd-enhancement, but also resolution and tissue contrast, might have contributed to this.</ce:para></abstract></abstracts><source srcid="19783" type="j" country="usa"><sourcetitle>Seminars in Arthritis and Rheumatism</sourcetitle><sourcetitle-abbrev>Semin. Arthritis Rheum.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Seminars in Arthritis and Rheumatism</translated-sourcetitle><issn type="electronic">1532866X</issn><issn type="print">00490172</issn><codencode>SAHRB</codencode><volisspag><voliss volume="51" issue="4"/><pagerange first="929" last="932"/></volisspag><publicationyear first="2021"/><publicationdate><year>2021</year><month>08</month><day>01</day><date-text>August 2021</date-text></publicationdate><website><ce:e-address type="email">http://www.elsevier.com/inca/publications/store/6/2/3/3/3/2/index.htt</ce:e-address></website><publisher><publishername>W.B. Saunders</publishername></publisher></source><enhancement><classificationgroup><classifications type="ASJC"><classification>2745</classification><classification>2703</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications></classificationgroup></enhancement></head><tail><bibliography refcount="16"><reference id="1"><ref-info><ref-title><ref-titletext>Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0001</itemid><itemid idtype="SGR">84860919649</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Boyesen P.</ce:indexed-name><ce:surname>Boyesen</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Slatkowsky-Christensen B.</ce:indexed-name><ce:surname>Slatkowsky-Christensen</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Sesseng S.</ce:indexed-name><ce:surname>Sesseng</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>van der Heijde D.</ce:indexed-name><ce:surname>van der Heijde</ce:surname></author><author seq="6"><ce:initials>T.K.</ce:initials><ce:indexed-name>Kvien T.K.</ce:indexed-name><ce:surname>Kvien</ce:surname></author></ref-authors><ref-sourcetitle>Ann Rheum Dis</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="71" issue="6"/><pagerange first="899" last="904"/></ref-volisspag></ref-info><ref-fulltext>Haugen, I.K., Boyesen, P., Slatkowsky-Christensen, B., Sesseng, S., van der Heijde, D., Kvien, T.K., Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Ann Rheum Dis 71:6 (2012), 899–904.</ref-fulltext><ce:source-text>Haugen I.K., Boyesen P., Slatkowsky-Christensen B., Sesseng S., van der Heijde D., Kvien T.K.Associations between MRI-defined synovitis, bone marrow lesions and structural features and measures of pain and physical function in hand osteoarthritis. Ann Rheum Dis. 2012;71 (6):899–904.</ce:source-text></reference><reference id="2"><ref-info><ref-title><ref-titletext>MRI findings predict radiographic progression and development of erosions in hand osteoarthritis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0002</itemid><itemid idtype="SGR">84954326530</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname></author><author seq="2"><ce:initials>B.</ce:initials><ce:indexed-name>Slatkowsky-Christensen B.</ce:indexed-name><ce:surname>Slatkowsky-Christensen</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Boyesen P.</ce:indexed-name><ce:surname>Boyesen</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Sesseng S.</ce:indexed-name><ce:surname>Sesseng</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>van der Heijde D.</ce:indexed-name><ce:surname>van der Heijde</ce:surname></author><author seq="6"><ce:initials>T.K.</ce:initials><ce:indexed-name>Kvien T.K.</ce:indexed-name><ce:surname>Kvien</ce:surname></author></ref-authors><ref-sourcetitle>Ann Rheum Dis</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="75" issue="1"/><pagerange first="117" last="123"/></ref-volisspag></ref-info><ref-fulltext>Haugen, I.K., Slatkowsky-Christensen, B., Boyesen, P., Sesseng, S., van der Heijde, D., Kvien, T.K., MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Ann Rheum Dis 75:1 (2016), 117–123.</ref-fulltext><ce:source-text>Haugen I.K., Slatkowsky-Christensen B., Boyesen P., Sesseng S., van der Heijde D., Kvien T.K.MRI findings predict radiographic progression and development of erosions in hand osteoarthritis. Ann Rheum Dis. 2016;75 (1):117–23.</ce:source-text></reference><reference id="3"><ref-info><ref-title><ref-titletext>Report from the OMERACT hand osteoarthritis working group: set of core domains and preliminary set of instruments for use in clinical trials and observational studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0003</itemid><itemid idtype="SGR">84946562060</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Kloppenburg M.</ce:indexed-name><ce:surname>Kloppenburg</ce:surname></author><author seq="2"><ce:initials>P.</ce:initials><ce:indexed-name>Boyesen P.</ce:indexed-name><ce:surname>Bøyesen</ce:surname></author><author seq="3"><ce:initials>A.W.</ce:initials><ce:indexed-name>Visser A.W.</ce:indexed-name><ce:surname>Visser</ce:surname></author><author seq="4"><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Boers M.</ce:indexed-name><ce:surname>Boers</ce:surname></author><author seq="6"><ce:initials>A.</ce:initials><ce:indexed-name>Boonen A.</ce:indexed-name><ce:surname>Boonen</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Rheumatol</ref-sourcetitle><ref-publicationyear first="2015"/><ref-volisspag><voliss volume="42" issue="11"/><pagerange first="2190" last="2197"/></ref-volisspag></ref-info><ref-fulltext>Kloppenburg, M., Bøyesen, P., Visser, A.W., Haugen, I.K., Boers, M., Boonen, A., et al. Report from the OMERACT hand osteoarthritis working group: set of core domains and preliminary set of instruments for use in clinical trials and observational studies. J Rheumatol 42:11 (2015), 2190–2197.</ref-fulltext><ce:source-text>Kloppenburg M., Bøyesen P., Visser A.W., Haugen I.K., Boers M., Boonen A., et al. Report from the OMERACT hand osteoarthritis working group: set of core domains and preliminary set of instruments for use in clinical trials and observational studies. J Rheumatol. 2015;42 (11):2190–7.</ce:source-text></reference><reference id="4"><ref-info><ref-title><ref-titletext>Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0004</itemid><itemid idtype="SGR">85054550608</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Kloppenburg M.</ce:indexed-name><ce:surname>Kloppenburg</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Ramonda R.</ce:indexed-name><ce:surname>Ramonda</ce:surname></author><author seq="3"><ce:initials>K.</ce:initials><ce:indexed-name>Bobacz K.</ce:indexed-name><ce:surname>Bobacz</ce:surname></author><author seq="4"><ce:initials>W.Y.</ce:initials><ce:indexed-name>Kwok W.Y.</ce:indexed-name><ce:surname>Kwok</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>Elewaut D.</ce:indexed-name><ce:surname>Elewaut</ce:surname></author><author seq="6"><ce:initials>T.W.J.</ce:initials><ce:indexed-name>Huizinga T.W.J.</ce:indexed-name><ce:surname>Huizinga</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Ann Rheum Dis</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="77" issue="12"/><pagerange first="1757" last="1764"/></ref-volisspag></ref-info><ref-fulltext>Kloppenburg, M., Ramonda, R., Bobacz, K., Kwok, W.Y., Elewaut, D., Huizinga, T.W.J., et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77:12 (2018), 1757–1764.</ref-fulltext><ce:source-text>Kloppenburg M., Ramonda R., Bobacz K., Kwok W.Y., Elewaut D., Huizinga T.W.J., et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77 (12):1757–64.</ce:source-text></reference><reference id="5"><ref-info><ref-title><ref-titletext>A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0005</itemid><itemid idtype="SGR">85045580718</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.</ce:initials><ce:indexed-name>Aitken D.</ce:indexed-name><ce:surname>Aitken</ce:surname></author><author seq="2"><ce:initials>L.L.</ce:initials><ce:indexed-name>Laslett L.L.</ce:indexed-name><ce:surname>Laslett</ce:surname></author><author seq="3"><ce:initials>F.</ce:initials><ce:indexed-name>Pan F.</ce:indexed-name><ce:surname>Pan</ce:surname></author><author seq="4"><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Otahal P.</ce:indexed-name><ce:surname>Otahal</ce:surname></author><author seq="6"><ce:initials>N.</ce:initials><ce:indexed-name>Bellamy N.</ce:indexed-name><ce:surname>Bellamy</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Osteoarthr Cartil</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="26" issue="7"/><pagerange first="880" last="887"/></ref-volisspag></ref-info><ref-fulltext>Aitken, D., Laslett, L.L., Pan, F., Haugen, I.K., Otahal, P., Bellamy, N., et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthr Cartil 26:7 (2018), 880–887.</ref-fulltext><ce:source-text>Aitken D., Laslett L.L., Pan F., Haugen I.K., Otahal P., Bellamy N., et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthr Cartil2018;26 (7):880–7.</ce:source-text></reference><reference id="6"><ref-info><ref-title><ref-titletext>Results of a 6-week treatment with 10mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0006</itemid><itemid idtype="SGR">85075519551</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.P.B.</ce:initials><ce:indexed-name>Kroon F.P.B.</ce:indexed-name><ce:surname>Kroon</ce:surname></author><author seq="2"><ce:initials>M.C.</ce:initials><ce:indexed-name>Kortekaas M.C.</ce:indexed-name><ce:surname>Kortekaas</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Boonen A.</ce:indexed-name><ce:surname>Boonen</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Bohringer S.</ce:indexed-name><ce:surname>Bohringer</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Reijnierse M.</ce:indexed-name><ce:surname>Reijnierse</ce:surname></author><author seq="6"><ce:initials>F.R.</ce:initials><ce:indexed-name>Rosendaal F.R.</ce:indexed-name><ce:surname>Rosendaal</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lancet</ref-sourcetitle><ref-publicationyear first="2019"/><ref-volisspag><voliss volume="394"/><pagerange first="1993" last="2001"/></ref-volisspag></ref-info><ref-fulltext>Kroon, F.P.B., Kortekaas, M.C., Boonen, A., Bohringer, S., Reijnierse, M., Rosendaal, F.R., et al. Results of a 6-week treatment with 10mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet 394 (2019), 1993–2001.</ref-fulltext><ce:source-text>Kroon F.P.B., Kortekaas M.C., Boonen A., Bohringer S., Reijnierse M., Rosendaal F.R., et al. Results of a 6-week treatment with 10mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;394:1993–2001.</ce:source-text></reference><reference id="7"><ref-info><ref-title><ref-titletext>High levels of gadolinium deposition in the skin of a patient with normal renal function</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0007</itemid><itemid idtype="SGR">84960193713</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.R.</ce:initials><ce:indexed-name>Roberts D.R.</ce:indexed-name><ce:surname>Roberts</ce:surname></author><author seq="2"><ce:initials>S.M.</ce:initials><ce:indexed-name>Lindhorst S.M.</ce:indexed-name><ce:surname>Lindhorst</ce:surname></author><author seq="3"><ce:initials>C.T.</ce:initials><ce:indexed-name>Welsh C.T.</ce:indexed-name><ce:surname>Welsh</ce:surname></author><author seq="4"><ce:initials>K.R.</ce:initials><ce:indexed-name>Maravilla K.R.</ce:indexed-name><ce:surname>Maravilla</ce:surname></author><author seq="5"><ce:initials>M.N.</ce:initials><ce:indexed-name>Herring M.N.</ce:indexed-name><ce:surname>Herring</ce:surname></author><author seq="6"><ce:initials>K.A.</ce:initials><ce:indexed-name>Braun K.A.</ce:indexed-name><ce:surname>Braun</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Invest Radiol</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="51" issue="5"/><pagerange first="280" last="289"/></ref-volisspag></ref-info><ref-fulltext>Roberts, D.R., Lindhorst, S.M., Welsh, C.T., Maravilla, K.R., Herring, M.N., Braun, K.A., et al. High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol 51:5 (2016), 280–289.</ref-fulltext><ce:source-text>Roberts D.R., Lindhorst S.M., Welsh C.T., Maravilla K.R., Herring M.N., Braun K.A., et al. High levels of gadolinium deposition in the skin of a patient with normal renal function. Invest Radiol. 2016;51 (5):280–9.</ce:source-text></reference><reference id="8"><ref-info><ref-title><ref-titletext>Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0008</itemid><itemid idtype="SGR">84992161278</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Maximova N.</ce:indexed-name><ce:surname>Maximova</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Gregori M.</ce:indexed-name><ce:surname>Gregori</ce:surname></author><author seq="3"><ce:initials>F.</ce:initials><ce:indexed-name>Zennaro F.</ce:indexed-name><ce:surname>Zennaro</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Sonzogni A.</ce:indexed-name><ce:surname>Sonzogni</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Simeone R.</ce:indexed-name><ce:surname>Simeone</ce:surname></author><author seq="6"><ce:initials>D.</ce:initials><ce:indexed-name>Zanon D.</ce:indexed-name><ce:surname>Zanon</ce:surname></author></ref-authors><ref-sourcetitle>Radiology</ref-sourcetitle><ref-publicationyear first="2016"/><ref-volisspag><voliss volume="281" issue="2"/><pagerange first="418" last="426"/></ref-volisspag></ref-info><ref-fulltext>Maximova, N., Gregori, M., Zennaro, F., Sonzogni, A., Simeone, R., Zanon, D., Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 281:2 (2016), 418–426.</ref-fulltext><ce:source-text>Maximova N., Gregori M., Zennaro F., Sonzogni A., Simeone R., Zanon D.Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology. 2016;281 (2):418–26.</ce:source-text></reference><reference id="9"><ref-info><ref-title><ref-titletext>Gadolinium deposition in brain: current scientific evidence and future perspectives</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0009</itemid><itemid idtype="SGR">85054819392</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.J.</ce:initials><ce:indexed-name>Guo B.J.</ce:indexed-name><ce:surname>Guo</ce:surname></author><author seq="2"><ce:initials>Z.L.</ce:initials><ce:indexed-name>Yang Z.L.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="3"><ce:initials>L.J.</ce:initials><ce:indexed-name>Zhang L.J.</ce:indexed-name><ce:surname>Zhang</ce:surname></author></ref-authors><ref-sourcetitle>Front Mol Neurosci</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="11"/><pagerange first="335"/></ref-volisspag></ref-info><ref-fulltext>Guo, B.J., Yang, Z.L., Zhang, L.J., Gadolinium deposition in brain: current scientific evidence and future perspectives. Front Mol Neurosci, 11, 2018, 335.</ref-fulltext><ce:source-text>Guo B.J., Yang Z.L., Zhang L.J.Gadolinium deposition in brain: current scientific evidence and future perspectives. Front Mol Neurosci. 2018;11:335</ce:source-text></reference><reference id="10"><ref-info><ref-title><ref-titletext>Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the canadian association of radiologists</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0010</itemid><itemid idtype="ARTNUM">2054358118778573</itemid><itemid idtype="SGR">85062991715</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>N.</ce:initials><ce:indexed-name>Schieda N.</ce:indexed-name><ce:surname>Schieda</ce:surname></author><author seq="2"><ce:initials>J.I.</ce:initials><ce:indexed-name>Blaichman J.I.</ce:indexed-name><ce:surname>Blaichman</ce:surname></author><author seq="3"><ce:initials>A.F.</ce:initials><ce:indexed-name>Costa A.F.</ce:indexed-name><ce:surname>Costa</ce:surname></author><author seq="4"><ce:initials>R.</ce:initials><ce:indexed-name>Glikstein R.</ce:indexed-name><ce:surname>Glikstein</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Hurrell C.</ce:indexed-name><ce:surname>Hurrell</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>James M.</ce:indexed-name><ce:surname>James</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Can J Kidney Health Dis</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="5"/></ref-volisspag></ref-info><ref-fulltext>Schieda, N., Blaichman, J.I., Costa, A.F., Glikstein, R., Hurrell, C., James, M., et al. Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the canadian association of radiologists. Can J Kidney Health Dis, 5, 2018, 2054358118778573.</ref-fulltext><ce:source-text>Schieda N., Blaichman J.I., Costa A.F., Glikstein R., Hurrell C., James M., et al. Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the canadian association of radiologists. Can J Kidney Health Dis. 2018;5:2054358118778573.</ce:source-text></reference><reference id="11"><ref-info><ref-title><ref-titletext>Improving domain definition and outcome instrument selection: lessons learned for OMERACT from imaging</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0011</itemid><itemid idtype="SGR">85108007533</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>D.E.B.</ce:initials><ce:indexed-name>Maria Antonietta D'Agostino D.E.B.</ce:indexed-name><ce:surname>Maria Antonietta D'Agostino</ce:surname></author><author seq="2"><ce:initials>L.J.</ce:initials><ce:indexed-name>Maxwell L.J.</ce:indexed-name><ce:surname>Maxwell</ce:surname><ce:given-name>Lara J</ce:given-name></author><author seq="3"><ce:initials>S.M.</ce:initials><ce:indexed-name>Cembalo S.M.</ce:indexed-name><ce:surname>Cembalo</ce:surname><ce:given-name>Sam Michel</ce:given-name></author><author seq="4"><ce:initials>A.M.</ce:initials><ce:indexed-name>Hoens A.M.</ce:indexed-name><ce:surname>Hoens</ce:surname><ce:given-name>Alison Maria</ce:given-name></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Hofstetter C.</ce:indexed-name><ce:surname>Hofstetter</ce:surname><ce:given-name>Catherine</ce:given-name></author><author seq="6"><ce:initials>C.</ce:initials><ce:indexed-name>Zabalan C.</ce:indexed-name><ce:surname>Zabalan</ce:surname><ce:given-name>Codruta</ce:given-name></author><author seq="7"><ce:initials>P.</ce:initials><ce:indexed-name>Bird P.</ce:indexed-name><ce:surname>Bird</ce:surname><ce:given-name>Paul</ce:given-name></author><author seq="8"><ce:initials>R.</ce:initials><ce:indexed-name>Christensen R.</ce:indexed-name><ce:surname>Christensen</ce:surname><ce:given-name>Robin</ce:given-name></author><author seq="9"><ce:initials>M.D.</ce:initials><ce:indexed-name>Wit M.D.</ce:indexed-name><ce:surname>Wit</ce:surname><ce:given-name>Maarten de</ce:given-name></author><author seq="10"><ce:initials>A.S.</ce:initials><ce:indexed-name>Doria A.S.</ce:indexed-name><ce:surname>Doria</ce:surname><ce:given-name>Andrea S</ce:given-name></author><author seq="11"><ce:initials>W.</ce:initials><ce:indexed-name>Maksymowych W.</ce:indexed-name><ce:surname>Maksymowych</ce:surname><ce:given-name>Walter</ce:given-name></author><author seq="12"><ce:initials>W.M.</ce:initials><ce:indexed-name>Oo W.M.</ce:indexed-name><ce:surname>Oo</ce:surname><ce:given-name>Win Min</ce:given-name></author><author seq="13"><ce:initials>M.</ce:initials><ce:indexed-name>Ostergaard M.</ce:indexed-name><ce:surname>Østergaard</ce:surname><ce:given-name>Mikkel</ce:given-name></author><author seq="14"><ce:initials>T.</ce:initials><ce:indexed-name>Serban T.</ce:indexed-name><ce:surname>Serban</ce:surname><ce:given-name>Teodora</ce:given-name></author><author seq="15"><ce:initials>V.S.S.L.</ce:initials><ce:indexed-name>Terslev V.S.S.L.</ce:indexed-name><ce:surname>Terslev</ce:surname></author><author seq="16"><ce:initials>M.A.V.</ce:initials><ce:indexed-name>Rossum M.A.V.</ce:indexed-name><ce:surname>Rossum</ce:surname><ce:given-name>Marion A van</ce:given-name></author><author seq="17"><ce:initials>P.G.</ce:initials><ce:indexed-name>Conaghan P.G.</ce:indexed-name><ce:surname>Conaghan</ce:surname><ce:given-name>Philip G</ce:given-name></author><author seq="18"><ce:initials>M.</ce:initials><ce:indexed-name>Boers M.</ce:indexed-name><ce:surname>Boers</ce:surname><ce:given-name>Maarten</ce:given-name></author></ref-authors><ref-sourcetitle>Semin Arthritis Rheum</ref-sourcetitle><ref-publicationyear first="2021"/></ref-info><ref-fulltext>Maria Antonietta D'Agostino, D.E.B., Maxwell, Lara J, Cembalo, Sam Michel, Hoens, Alison Maria, Hofstetter, Catherine, Zabalan, Codruta, Bird, Paul, Christensen, Robin, Wit, Maarten de, Doria, Andrea S, Maksymowych, Walter, Oo, Win Min, Østergaard, Mikkel, Serban, Teodora, Terslev, V.S.S.L., Rossum, Marion A van, Conaghan, Philip G, Boers, Maarten, Improving domain definition and outcome instrument selection: lessons learned for OMERACT from imaging. Semin Arthritis Rheum, 2021.</ref-fulltext><ce:source-text>Maria Antonietta D'Agostino D.E.B., Lara J Maxwell, Sam Michel Cembalo, Alison Maria Hoens, Catherine Hofstetter, Codruta Zabalan, Paul Bird, Robin Christensen, Maarten de Wit, Andrea S Doria, Walter Maksymowych, Win Min Oo, Mikkel Østergaard, Teodora Serban, V.S.S.L. Terslev, Marion A van Rossum, Philip G Conaghan, Maarten Boers. Improving domain definition and outcome instrument selection: lessons learned for OMERACT from imaging. Semin Arthritis Rheum. 2021.</ce:source-text></reference><reference id="12"><ref-info><ref-title><ref-titletext>Iterative development and reliability of the OMERACT hand osteoarthritis MRI scoring system</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0012</itemid><itemid idtype="SGR">84893568799</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.K.</ce:initials><ce:indexed-name>Haugen I.K.</ce:indexed-name><ce:surname>Haugen</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Ostergaard M.</ce:indexed-name><ce:surname>Ostergaard</ce:surname></author><author seq="3"><ce:initials>I.</ce:initials><ce:indexed-name>Eshed I.</ce:indexed-name><ce:surname>Eshed</ce:surname></author><author seq="4"><ce:initials>F.M.</ce:initials><ce:indexed-name>McQueen F.M.</ce:indexed-name><ce:surname>McQueen</ce:surname></author><author seq="5"><ce:initials>P.</ce:initials><ce:indexed-name>Bird P.</ce:indexed-name><ce:surname>Bird</ce:surname></author><author seq="6"><ce:initials>F.</ce:initials><ce:indexed-name>Gandjbakhch F.</ce:indexed-name><ce:surname>Gandjbakhch</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Rheumatol</ref-sourcetitle><ref-publicationyear first="2014"/><ref-volisspag><voliss volume="41" issue="2"/><pagerange first="386" last="391"/></ref-volisspag></ref-info><ref-fulltext>Haugen, I.K., Ostergaard, M., Eshed, I., McQueen, F.M., Bird, P., Gandjbakhch, F., et al. Iterative development and reliability of the OMERACT hand osteoarthritis MRI scoring system. J Rheumatol 41:2 (2014), 386–391.</ref-fulltext><ce:source-text>Haugen I.K., Ostergaard M., Eshed I., McQueen F.M., Bird P., Gandjbakhch F., et al. Iterative development and reliability of the OMERACT hand osteoarthritis MRI scoring system. J Rheumatol. 2014;41 (2):386–91.</ce:source-text></reference><reference id="13"><ref-info><ref-title><ref-titletext>Development and reliability of the OMERACT thumb base osteoarthritis magnetic resonance imaging scoring system</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0013</itemid><itemid idtype="SGR">85029949343</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.P.B.</ce:initials><ce:indexed-name>Kroon F.P.B.</ce:indexed-name><ce:surname>Kroon</ce:surname></author><author seq="2"><ce:initials>P.G.</ce:initials><ce:indexed-name>Conaghan P.G.</ce:indexed-name><ce:surname>Conaghan</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Foltz V.</ce:indexed-name><ce:surname>Foltz</ce:surname></author><author seq="4"><ce:initials>F.</ce:initials><ce:indexed-name>Gandjbakhch F.</ce:indexed-name><ce:surname>Gandjbakhch</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Peterfy C.</ce:indexed-name><ce:surname>Peterfy</ce:surname></author><author seq="6"><ce:initials>I.</ce:initials><ce:indexed-name>Eshed I.</ce:indexed-name><ce:surname>Eshed</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Rheumatol</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="44" issue="11"/><pagerange first="1694" last="1698"/></ref-volisspag></ref-info><ref-fulltext>Kroon, F.P.B., Conaghan, P.G., Foltz, V., Gandjbakhch, F., Peterfy, C., Eshed, I., et al. Development and reliability of the OMERACT thumb base osteoarthritis magnetic resonance imaging scoring system. J Rheumatol 44:11 (2017), 1694–1698.</ref-fulltext><ce:source-text>Kroon F.P.B., Conaghan P.G., Foltz V., Gandjbakhch F., Peterfy C., Eshed I., et al. Development and reliability of the OMERACT thumb base osteoarthritis magnetic resonance imaging scoring system. J Rheumatol. 2017;44 (11):1694–8.</ce:source-text></reference><reference id="14"><ref-info><ref-title><ref-titletext>OMERACT filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0014</itemid><itemid idtype="SGR">85070203338</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Boers M.</ce:indexed-name><ce:surname>Boers</ce:surname></author><author seq="2"><ce:initials>D.E.</ce:initials><ce:indexed-name>Beaton D.E.</ce:indexed-name><ce:surname>Beaton</ce:surname></author><author seq="3"><ce:initials>B.J.</ce:initials><ce:indexed-name>Shea B.J.</ce:indexed-name><ce:surname>Shea</ce:surname></author><author seq="4"><ce:initials>L.J.</ce:initials><ce:indexed-name>Maxwell L.J.</ce:indexed-name><ce:surname>Maxwell</ce:surname></author><author seq="5"><ce:initials>S.J.</ce:initials><ce:indexed-name>Bartlett S.J.</ce:indexed-name><ce:surname>Bartlett</ce:surname></author><author seq="6"><ce:initials>C.O.</ce:initials><ce:indexed-name>Bingham C.O.</ce:indexed-name><ce:surname>Bingham</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Rheumatol</ref-sourcetitle><ref-publicationyear first="2019"/><ref-volisspag><voliss volume="46" issue="8"/><pagerange first="1021" last="1027"/></ref-volisspag></ref-info><ref-fulltext>Boers, M., Beaton, D.E., Shea, B.J., Maxwell, L.J., Bartlett, S.J., Bingham, C.O., et al. OMERACT filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. J Rheumatol 46:8 (2019), 1021–1027.</ref-fulltext><ce:source-text>Boers M., Beaton D.E., Shea B.J., Maxwell L.J., Bartlett S.J., Bingham C.O., 3rd, et al. OMERACT filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. J Rheumatol. 2019;46 (8):1021–7.</ce:source-text></reference><reference id="15"><ref-info><ref-title><ref-titletext>A hospital-based observational cohort study exploring pain and biomarkers in patients with hand osteoarthritis in Norway: the nor-hand protocol</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0015</itemid><itemid idtype="ARTNUM">e016938</itemid><itemid idtype="SGR">85029912697</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Gloersen M.</ce:indexed-name><ce:surname>Gloersen</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Mulrooney E.</ce:indexed-name><ce:surname>Mulrooney</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Mathiessen A.</ce:indexed-name><ce:surname>Mathiessen</ce:surname></author><author seq="4"><ce:initials>H.B.</ce:initials><ce:indexed-name>Hammer H.B.</ce:indexed-name><ce:surname>Hammer</ce:surname></author><author seq="5"><ce:initials>B.</ce:initials><ce:indexed-name>Slatkowsky-Christensen B.</ce:indexed-name><ce:surname>Slatkowsky-Christensen</ce:surname></author><author seq="6"><ce:initials>K.</ce:initials><ce:indexed-name>Faraj K.</ce:indexed-name><ce:surname>Faraj</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>BMJ Open</ref-sourcetitle><ref-publicationyear first="2017"/><ref-volisspag><voliss volume="7" issue="9"/></ref-volisspag></ref-info><ref-fulltext>Gloersen, M., Mulrooney, E., Mathiessen, A., Hammer, H.B., Slatkowsky-Christensen, B., Faraj, K., et al. A hospital-based observational cohort study exploring pain and biomarkers in patients with hand osteoarthritis in Norway: the nor-hand protocol. BMJ Open, 7(9), 2017, e016938.</ref-fulltext><ce:source-text>Gloersen M., Mulrooney E., Mathiessen A., Hammer H.B., Slatkowsky-Christensen B., Faraj K., et al. A hospital-based observational cohort study exploring pain and biomarkers in patients with hand osteoarthritis in Norway: the nor-hand protocol. BMJ Open. 2017;7 (9):e016938.</ce:source-text></reference><reference id="16"><ref-info><ref-title><ref-titletext>New scoring system in assessment of Hoffa's fat pad synovitis: a comparative study with established scoring systems</ref-titletext></ref-title><refd-itemidlist><itemid idtype="FRAGMENTID">bib0016</itemid><itemid idtype="SGR">85107962632</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Hagiwara S.</ce:indexed-name><ce:surname>Hagiwara</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Yang A.</ce:indexed-name><ce:surname>Yang</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Takao S.</ce:indexed-name><ce:surname>Takao</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Kaneko Y.</ce:indexed-name><ce:surname>Kaneko</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Nozaki T.</ce:indexed-name><ce:surname>Nozaki</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Yoshioka H.</ce:indexed-name><ce:surname>Yoshioka</ce:surname></author></ref-authors><ref-sourcetitle>World J Radiol</ref-sourcetitle><ref-publicationyear first="2018"/><ref-volisspag><voliss volume="10" issue="11"/><pagerange first="162" last="171"/></ref-volisspag></ref-info><ref-fulltext>Hagiwara, S., Yang, A., Takao, S., Kaneko, Y., Nozaki, T., Yoshioka, H., New scoring system in assessment of Hoffa's fat pad synovitis: a comparative study with established scoring systems. World J Radiol 10:11 (2018), 162–171.</ref-fulltext><ce:source-text>Hagiwara S., Yang A., Takao S., Kaneko Y., Nozaki T., Yoshioka H.New scoring system in assessment of Hoffa's fat pad synovitis: a comparative study with established scoring systems. World J Radiol. 2018;10 (11):162–71.</ce:source-text></reference></bibliography></tail></bibrecord></item></xocs:item></xocs:doc>